Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)
Titel:
Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)
Auteur:
Marabelle, A. Ghiringhelli, F. Ayyoub, M. Tartour, E. Adotevi, O. Loriot, Y. Lambotte, O. Cupissol, D. Damotte, D. Adam, J. Bonvalet, M. Petre Lazar, B. Licour, M. Chaput, N.